By providing an alternative means of targeting the cell-cycle deregulation and accelerated proliferation typical of aggressive luminal breast cancers, interfering with the c-Src–FOXM1 positive feedback loop may improve patient outcomes. This evidence concerns the gene SRC and breast cancer.